Fangzhou Introduces Game-Changing AI for Healthcare
At a recent healthcare conference in Shanghai, Fangzhou Inc. (“Fangzhou” or the “Company”) (HKSE: 6086), a pioneer in AI-driven Internet healthcare solutions, revealed its groundbreaking “XingShi” Large Language Model (XS LLM). This innovative AI technology aims to tackle significant challenges in chronic disease management, ultimately enhancing service efficiency, personalizing patient care, and optimizing physicians' valuable time.
Understanding the Capabilities of XS LLM
XS LLM harnesses advanced multimodal capabilities, which include not just text but also image and speech recognition combined with natural language processing. In addition, it features extensive medical knowledge and reasoning abilities, setting new performance standards in medical AI. The system operates five specialized intelligent agents: “AI Knowledge Agent”, “AI Guidance Agent”, “AI Pre-Consult Agent”, “AI Doctor Assistant”, and “AI-Electronic Medical Record (EMR) Agent”, collectively forming a comprehensive service model that encompasses all aspects of chronic disease management.
Applications of XS LLM
The XS LLM is the core digital brain powering Fangzhou’s suite of applications, which includes the AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and an AI-Powered Search tool. Each application is tailored to address specific clinical and patient needs, ensuring real-time, precise interventions for medication guidance, patient education, diagnostic assistance, and easy access to medical references.
A Vision for the Future
Dr. Xie Fangmin, the founder, chairman, and CEO of Fangzhou, emphasized the significance of this launch, stating, “This launch is not simply a product milestone, but a strategic inflection point. XS LLM provides the technical foundation to embed AI across all layers of chronic disease management, enabling precision, scale, and accessibility in healthcare delivery.” Dr. Fangmin’s vision underscores the commitment Fangzhou has towards revolutionizing healthcare.
Fangzhou’s AI Development Journey
The unveiling of XS LLM is a testament to Fangzhou’s continuous development in AI technologies. The company has progressively built its H2H (Hospital-to-Home) digital ecosystem, expanded its AI-powered customer service, and now, with XS LLM, transitions into a robust enterprise-grade medical application. The ground-breaking technology is positioned to lead in China’s rapidly evolving AI landscape, particularly as government policies push for greater industrial adoption of AI in healthcare.
Empowering Healthcare Providers and Patients
With 52.8 million registered users and over 229,000 physicians tapped into its platform, Fangzhou is poised to change the face of chronic disease management. The aim is to provide personalized medical care backed by AI solutions that ensure more precise treatment and better patient outcomes, reinforcing Fangzhou's mission of enhancing healthcare accessibility for all.
Contact for More Information
For further inquiries or to learn more about Fangzhou Inc., interested parties can reach out to:
Xingwei Zhao
Associate Director of Public Relations
Email: pr@jianke.com
Frequently Asked Questions
What is the purpose of the XS LLM?
The XS LLM is designed to improve chronic disease management by increasing efficiency in services and personalizing patient care.
Who is behind Fangzhou?
Fangzhou is led by Dr. Xie Fangmin, who is the founder, chairman, and CEO of the company.
How many users does Fangzhou currently have?
Fangzhou serves 52.8 million registered users and connects with 229,000 physicians as of mid-2025.
What technologies does XS LLM integrate?
XS LLM integrates image and speech recognition, natural language processing, and a large medical knowledge database.
What is Fangzhou’s vision for the future?
Fangzhou aims to enhance healthcare delivery using AI, making medical services more accessible, precise, and scalable.
